<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04133792</url>
  </required_header>
  <id_info>
    <org_study_id>2018-000814-39</org_study_id>
    <nct_id>NCT04133792</nct_id>
  </id_info>
  <brief_title>Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)</brief_title>
  <acronym>PiSCATIN</acronym>
  <official_title>Effect of Simvastatin on the Prognosis of Primary Sclerosing Cholangitis (PSC); A Randomized, Double-blind, Placebo Controlled Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annika Bergquist</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo controlled multicenter study.&#xD;
&#xD;
      A total of 700 patients will be included.&#xD;
&#xD;
      The study will include patients with primary sclerosing cholangitis (PSC) for daily intake of&#xD;
      40 mg simvastatin/placebo for 5 years. The aim is to study effect of prognosis of PSC by long&#xD;
      term intake of simvastatin. Outcome measures are death, liver transplantation,&#xD;
      cholangiocarcinoma or bleeding from esophageal varices.&#xD;
&#xD;
      Subjects will be randomized (1:1) between Simvastatin and placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">May 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from the date of randomization to the date of death, assessed up to 5 years.</time_frame>
    <description>Overall survival from time to randomization to death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Listing for liver transplantation</measure>
    <time_frame>Time from the date of randomization to the date of listing for liver transplantation, assessed up to 5 years.</time_frame>
    <description>Date the subject is getting registered on the waiting list for liver transplantation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first varices bleeding</measure>
    <time_frame>Time from the date of randomization to the date of the first varices bleeding, assessed up to 5 years.</time_frame>
    <description>Date of the subject's first varices bleeding according to hospital patient records.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to diagnosis of cholangiocarcinoma, gall bladder cancer, or hepatocellular cancer.</measure>
    <time_frame>Time from the date of randomization to cancer diagnosis, assessed up to 5 years.</time_frame>
    <description>Diagnosis of cancer of bile duct cancer or gall bladder, or hepatocellular cancer according to hospital patient records.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on serum concentration of alkaline phosphatase (ALP).</measure>
    <time_frame>Assessed yearly up to 5 years.</time_frame>
    <description>Assessment of changes in the serum concentration of alkaline phosphatase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on serum concentration of bilirubin</measure>
    <time_frame>Assessed yearly up to 5 years.</time_frame>
    <description>Assessment of changes in the serum concentration of bilirubin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the progress of PSC by liver failure measurement</measure>
    <time_frame>Assessed at every visit except the 3 months visit, up to 5 years.</time_frame>
    <description>Assessment of liver failure using Model for End Stage Liver Disease (MELD) Score (biochemical and clinical variables).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the progress of PSC by liver failure measurement.</measure>
    <time_frame>Assessed at every visit except the 3 months visit, up to 5 years.</time_frame>
    <description>Assessment of liver failure using Child Pugh Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the progress of PSC assessed by cholangiography at MRI.</measure>
    <time_frame>Assessed at inclusion and the 60 months visit.</time_frame>
    <description>Progress assessed by cholangiography MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the progress of PSC assessed by elastography</measure>
    <time_frame>Assessed yearly up to 5 years.</time_frame>
    <description>Assessment of fibrosis stage using elastography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the progress of PSC assessed by clinical symptoms</measure>
    <time_frame>Assessed yearly up to 5 years.</time_frame>
    <description>Assessment of symptoms including itching and bacterial cholangitis that requires treatment, ascites and encephalopathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the progress of PSC assessed by measurement of biliary dysplasia</measure>
    <time_frame>Assessed upon clinical indication, up to 5 years.</time_frame>
    <description>Biliary dysplasia from brush samples taken at endoscopic retrograde cholangiopancreatography (ERCP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the development of colon cancer or colon dysplasia.</measure>
    <time_frame>Assessed at 60 months.</time_frame>
    <description>Development of colon cancer and/or colon dysplasia according to hospital patient records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on the progress of PSC assessed by serum fibrosis markers</measure>
    <time_frame>Assessed yearly up to 5 years</time_frame>
    <description>Fib-4, ELF (if funded)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 40 mg administered orally daily for 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Simvastatin 40 mg administered orally daily for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 40mg</intervention_name>
    <description>40 mg orally daily for 5 years.</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>40 mg orally daily for 5 years.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PSC verified by cholangiography or liver biopsy, with or without irritable bowel&#xD;
             disease (IBD).&#xD;
&#xD;
          -  Men and women between ≥18 years and ≤75 years.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  A magnetic resonance imaging (MRI) or Magnetic resonance cholangiopancreatography&#xD;
             (MRCP) performed within 4 months prior to randomization.&#xD;
&#xD;
          -  Colonoscopy performed within 24 months prior to randomization, if known IBD.&#xD;
&#xD;
          -  For women of childbearing potential efficient contraceptive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects on waiting list for transplantation&#xD;
&#xD;
          -  Transplanted subjects&#xD;
&#xD;
          -  Previous variceal bleeding&#xD;
&#xD;
          -  Previous hepatobiliary malignancy&#xD;
&#xD;
          -  Subjects with secondary sclerosing cholangitis&#xD;
&#xD;
          -  Intake of any type of statins within 3 months prior to randmization&#xD;
&#xD;
          -  Known intolerance to simvastatin.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annika Bergquist, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annika Bergquist, MD PhD</last_name>
    <phone>0707214907</phone>
    <phone_ext>+46</phone_ext>
    <email>annika.bergquist@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Klein, PhD</last_name>
    <phone>08-524 837 32</phone>
    <phone_ext>+46</phone_ext>
    <email>amanda.klein@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skåne Universitetssjukhus</name>
      <address>
        <city>Malmö</city>
        <state>Skåne</state>
        <zip>222 42</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Nilsson</last_name>
    </contact>
    <contact_backup>
      <last_name>emma.nilsson@skane.se</last_name>
    </contact_backup>
    <investigator>
      <last_name>Emma Nilsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <state>Västerbotten</state>
        <zip>907 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mårten Werner</last_name>
      <email>marten.warner@umu.se</email>
    </contact>
    <investigator>
      <last_name>Mårten Warner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <state>Västra Götaland</state>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanns-Ulrich Marschall</last_name>
      <email>hanns-ulrich.marschall@gu.se</email>
    </contact>
    <investigator>
      <last_name>Hanns-Ulrich Marschall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Södra Älvsborgs sjukhus</name>
      <address>
        <city>Borås</city>
        <zip>501 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iris Posserud</last_name>
      <email>iris.posserud@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Marie A Andersson</last_name>
      <email>marie.a.andersson@vgregion.se</email>
    </contact_backup>
    <investigator>
      <last_name>Iris Posserud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset Östra</name>
      <address>
        <city>Göteborg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Papachrysos</last_name>
      <email>nikolaos.papachrysos@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Elin Hultgren</last_name>
      <email>elin.hultgren@vgregion.se</email>
    </contact_backup>
    <investigator>
      <last_name>Nikolaos Papachrysos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karlstads centralsjukhus</name>
      <address>
        <city>Karlstad</city>
        <zip>652 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Imanté Lasyté</last_name>
      <email>imante.lasyte@regionvarmland.se</email>
    </contact>
    <contact_backup>
      <last_name>Theres Holmblad</last_name>
      <email>theres.holmblad@regionvarmland.se</email>
    </contact_backup>
    <investigator>
      <last_name>Imanté Lasyté</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capio S:t Görans sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>112 19</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotte Söderman</last_name>
      <email>charlotte.soderman@capiostgoran.se</email>
    </contact>
    <investigator>
      <last_name>Charlotte Söderman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ersta sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>116 28</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Izabella Jancewska</last_name>
    </contact>
    <contact_backup>
      <last_name>izabella.janczewska@erstadiakoni.se</last_name>
    </contact_backup>
    <investigator>
      <last_name>Izabella Jancewska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>141 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika Bergquist</last_name>
      <phone>70 7214907</phone>
      <phone_ext>460</phone_ext>
      <email>annika.bergquist@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Susanne Bouiche</last_name>
    </contact_backup>
    <investigator>
      <last_name>Annika Bergquist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotta Hedin</last_name>
      <email>charlotta.hedin@ki.se</email>
    </contact>
    <investigator>
      <last_name>Charlotta Hedin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyds sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>182 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Lördal</last_name>
      <email>mikael.lordal@sll.se</email>
    </contact>
    <investigator>
      <last_name>Mikael Lördal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norra Älvsborgs länssjukhus</name>
      <address>
        <city>Trollhättan</city>
        <zip>461 73</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Knutsson</last_name>
      <email>marie.knutsson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Marie Knutsson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Rorsman</last_name>
      <email>fredrik.rorsman@medsci.uu.se</email>
    </contact>
    <investigator>
      <last_name>Fredrik Rorsman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Örebro Universitetssjukhus</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils Nyhlin</last_name>
      <email>nils.nyhlin@regionorebrolan.se</email>
    </contact>
    <investigator>
      <last_name>Nils Nyhlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset i Linköping</name>
      <address>
        <city>Linköping</city>
        <state>Östergötland</state>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stergios Kechagias</last_name>
      <email>stergios.kechagias@liu.se</email>
    </contact>
    <investigator>
      <last_name>Stergios Kechagias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Annika Bergquist</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

